Medical Science Liaison; MD Gastroenterology, Neuroimmunology & Allergy

Department: Medical / Scientific Affairs

Employment Type: Full-Time

BÜHLMANN Diagnostics is seeking an experienced, highly credible Medical Science Liaison (MSL) to serve as a field-based scientific and clinical expert supporting the company’s diagnostic portfolio across the United States.

The primary focus of this position will be Gastroenterology, with particular emphasis on advancing clinical understanding and appropriate utilization of fecal calprotectin (fCAL) testing. The MSL will also provide scientific and medical support for BÜHLMANN’s growing portfolios in Neuroimmunology and Allergy.

The successful candidate will be an MD or equivalent physician-level medical professional capable of engaging peer-to-peer with gastroenterologists, primary care physicians, laboratory medical directors, pathologists, neurologists, allergists, academic investigators, and other healthcare leaders.

A central objective of the role will be to expand physician understanding of the clinical utility of non-invasive biomarkers-particularly fecal calprotectin-and support evidence‑based diagnostic pathways that help clinicians determine which patients may require additional invasive diagnostic evaluation.

This individual will operate at the intersection of clinical medicine, laboratory diagnostics, scientific education, and market development, helping translate scientific evidence into clinical practice while maintaining the highest standards of medical and scientific integrity.

• Serve as BÜHLMANN’s primary field‑based medical expert for fecal calprotectin (fCAL) and other gastroenterology biomarkers.
• Conduct peer‑to‑peer scientific discussions with gastroenterologists, primary care physicians, advanced practice providers, laboratory directors, pathologists, and other healthcare professionals regarding the appropriate clinical utilization of fecal calprotectin.
• Educate clinicians on the evidence supporting fecal calprotectin as a non‑invasive marker of intestinal inflammation and its role as an aid in differentiating inflammatory bowel disease from functional gastrointestinal disorders.
• Advance awareness of evidence‑based diagnostic pathways incorporating fecal calprotectin before referral for or progression to invasive diagnostic procedures when clinically appropriate.
• Work with GI practices, health systems, IDNs, academic institutions, and laboratories to identify barriers preventing appropriate utilization of fecal calprotectin testing.
• Support development of clinical algorithms and diagnostic pathways that incorporate fecal calprotectin into the evaluation of patients presenting with gastrointestinal symptoms.
• Educate PCPs and other referring clinicians on when fecal calprotectin testing may provide useful clinical information before GI referral.
• Partner with gastroenterology leaders to evaluate opportunities to improve patient triage, referral patterns, GI capacity utilization, and appropriate selection of patients for further diagnostic evaluation.
• Develop relationships with national and regional Key Opinion Leaders (KOLs) in gastroenterology and inflammatory bowel disease.
• Identify and support physician champions who can advance evidence‑based utilization of fecal calprotectin within their institutions and professional networks.
• Support scientific programs, advisory boards, investigator‑initiated research, publications, congress activities, and continuing medical education initiatives where appropriate.
• Engage neurologists, neuroimmunologists, allergists, immunologists, laboratory medical directors, and other relevant specialists regarding BÜHLMANN diagnostic solutions.
• Provide scientific education regarding disease biology, biomarkers, testing methodologies,…